14 PSA based intermediate endpoints to compare cancer specific survival difference between radiotherapy and radical prostatectomy for the treatment of localized prostate cancer

14 PSA based intermediate endpoints to compare cancer specific survival difference between radiotherapy and radical prostatectomy for the treatment of localized prostate cancer

Saved in:

Bibliographic Details
Main Authors:	P. Wiklund, U. Falagario, F. Pellegrino, A. Lantz, O. Akre
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168325000175
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Survival Benefit of Radical Prostatectomy in Newly Diagnosed Metastatic Prostate Cancer Varies by PSA Level and Site of Metastasis
by: Xin Zhang, et al.
Published: (2025-12-01)

Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer
by: Peerapon Sangthong, et al.
Published: (2025-07-01)

Robotic Radical Prostatectomy in Patients with Previous Prostate Surgery and Radiotherapy
by: Ömer Acar, et al.
Published: (2014-01-01)

Sexuality of prostate cancer patients following radical prostatectomy
by: M. E. Efremov, et al.
Published: (2025-06-01)

The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy
by: Heikki Seikkula, et al.
Published: (2024-11-01)

Oncological outcomes of patients with ductal adenocarcinoma of the prostate receiving radical prostatectomy or radiotherapy
by: Mengzhu Liu, et al.
Published: (2021-04-01)

The association between the interval from biopsy to radical prostatectomy and biochemical recurrence in patients with intermediate- and high-risk prostate cancer
by: Carolin Siech, et al.
Published: (2025-02-01)

Robot-Assisted Radical Prostatectomy in High-Risk Prostate Cancer
by: V. N. Pavlov, et al.
Published: (2021-12-01)

Recurrence of Prostate Cancer with Cutaneous Metastasis after Radical Prostatectomy
by: Parth Patel, et al.
Published: (2015-01-01)

PSA as the driving biomarker to manage low- and intermediate-risk prostate cancer patients in clinical practice
by: Enrico Ricevuto, et al.
Published: (2024-10-01)

Radical Prostatectomy and Intraoperative Radiation Therapy in High-Risk Prostate Cancer
by: Giansilvio Marchioro, et al.
Published: (2012-01-01)

RADICAL PROSTATECTOMY AND ROBOTIC RADIOSURGERY AS TREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER
by: E. A. Kipriyanov, et al.
Published: (2020-03-01)

The Role of Radical Prostatectomy in the Treatment of Patients with High-Risk Prostate Cancer
by: Barış Kuzgunbay, et al.
Published: (2015-09-01)

Prostate Imaging Reporting and Data System in prostate cancer staging and planning for radical prostatectomy
by: Mieszko Kozikowski, et al.
Published: (2019-03-01)

Secondary Analysis of PSA and BCR-Free Survival in Asian Prostate Cancer Patients
by: Gao X, et al.
Published: (2025-06-01)

Long‐term oncological outcomes after multimodal treatment for locally advanced prostate cancer
by: Fiorella L. Roldan, et al.
Published: (2024-09-01)

Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort study
by: Mats Steinholtz Ahlberg, et al.
Published: (2022-12-01)

P8 PSA biochemical recurrence after radical prostatectomy in cases with positive surgical margin
by: R. Okas, et al.
Published: (2025-07-01)

Distant ureteric metastasis of prostate cancer four years post radical prostatectomy
by: Sachin J. Joshi, et al.
Published: (2025-03-01)

Age-Specific Impact of Cribriform Pattern in Prostate Cancer Following Radical Prostatectomy
by: Ari S Hilibrand, et al.
Published: (2025-08-01)

Shaping Clinical Policy for Salvage Radiotherapy After Radical Prostatectomy in Prostate Cancer: Bridging the Gap Between Clinical Trials and Daily Practice
by: Piero Bettoli, et al.
Published: (2024-11-01)

The Prostate cancer–Exercise and Metformin randomised controlled feasibility Trial (Pre-EMpT) in men following active surveillance, radical prostatectomy and radiotherapy
by: Luke A. Robles, et al.
Published: (2025-05-01)

Intermediate-term oncological and functional outcomes in prostate cancer patients treated with perineal robot-assisted radical prostatectomy: A single center analysis
by: Umberto Carbonara, et al.
Published: (2023-10-01)

Comparison of efficacy of Retzius-sparing radical prostatectomy versus standard radical prostatectomy in the treatment of prostate cancer: a systematic review and meta-analysis
by: Weilun Gong, et al.
Published: (2025-05-01)

Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma
by: Christopher B. Baker, et al.
Published: (2016-01-01)

Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort
by: Shyam K. Tanguturi, et al.
Published: (2014-01-01)

Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation
by: Christos Kalaitzis, et al.
Published: (2014-01-01)

Survival benefit of radical prostatectomy in bone metastatic prostate cancer stratified by disease characteristics: A SEER-based retrospective analysis.
by: Xinxing Zhang, et al.
Published: (2025-01-01)

Survival benefit of radical prostatectomy in bone metastatic prostate cancer stratified by disease characteristics: A SEER-based retrospective analysis
by: Xinxing Zhang, et al.
Published: (2025-01-01)

A 5-Year Follow-Up of Patient-Reported Outcome Measures Following External Beam Radiotherapy or Radical Prostatectomy in Localised Prostate Cancer
by: Rowan V. David, et al.
Published: (2025-04-01)

Prognostic Significance of Lymphovascular Invasion in Clinically Localized Prostate Cancer after Radical Prostatectomy
by: Dilek Ertoy Baydar, et al.
Published: (2008-01-01)

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
by: Christa Babst, et al.
Published: (2022-01-01)

Clinical efficacy of cytoreductive radical prostatectomy in the treatment of oligometastatic hormone-sensitive prostate cancer
by: Feng Qi, et al.
Published: (2025-01-01)

Robot-Assisted Laparoscopic Radical Prostatectomy for Prostatic Metastatic Recurrence from Testicular Cancer
by: Kohei Hirose, et al.
Published: (2024-01-01)

Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions
by: Pirus Ghadjar, et al.
Published: (2012-01-01)

Association of Serum PSA, fPSA, and CEA Levels with Prognosis and Clinicopathological Characteristics in Prostate Cancer
by: Ahamed Y, et al.
Published: (2025-08-01)

REHABILITATION EFFECT OF CORRECTION OF ERECTILE DYSFUNCTION IN PATIENTS WHO UNDERWENT RADICAL PROSTATECTOMY FOR PROSTATE CANCER
by: A. T. Asratov, et al.
Published: (2018-06-01)

IMPACT OF PREOPERATIVE STAGING OF PROSTATIC CANCER ON POSITIVE SURGICAL MARGIN INCIDENCE FOLLOWING RADICAL PROSTATECTOMY
by: V. L. Medvedev, et al.
Published: (2019-02-01)

Apalutamide for high-risk localized prostate cancer following radical prostatectomy- A new Horizon
by: Mithilesh Yadav
Published: (2025-07-01)

Adverse Pathology After Radical Prostatectomy in Low- and Intermediate-Risk Prostate Cancer: A Propensity Score-Matched Analysis of Long-Term Health-Related Quality of Life
by: Michael Chaloupka, et al.
Published: (2025-08-01)